IFNA1 and cancer: One group is currently studying the use of intranasal IFN α as PrEP and PoEP in cancer patients (ClinicalTrials.gov Identifier: NCT04534725) and another is evaluating intravenous IFN α and rintatolimod, a double-stranded RNA designed to mimic viral infection and stimulate immunity in cancer patients with mCOVID-19 (ClinicalTrials.gov Identifier: NCT04379518).